Atlas Trials

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

Clinical trial NCT05959356 · RECRUITING

Trial details

NCT number
NCT05959356
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Colorectal Cancer
Start date
2023-11-09
Primary completion
2026-12-31
Enrollment
198

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.